<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00038649</url>
  </required_header>
  <id_info>
    <org_study_id>ID01-151</org_study_id>
    <nct_id>NCT00038649</nct_id>
  </id_info>
  <brief_title>Therapy of Early Chronic Phase CML With Higher-Dose Gleevec, Alpha Interferon, and Low-Dose Ara-C</brief_title>
  <official_title>Therapy of Early Chronic Phase Chronic Myelogenous Leukemia (CML) With Higher-Dose Gleevec (STI571)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>M.D. Anderson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>M.D. Anderson Cancer Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of this clinical research study is to see if higher doses of imatinib mesylate
      (Gleevec, STI571) can improve chronic myelogenous leukemia (CML) in chronic phase.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Imatinib mesylate is a new oral medication that blocks a protein that is responsible for CML

      Before treatment starts, patients will have a physical exam, blood tests, and a bone marrow
      study. The bone marrow will be removed with a large needle. Women able to have children will
      have a screening blood or urine test for pregnancy.

      Patients on this study will take 400 mg of imatinib twice daily (morning and evening). If you
      have side effects, the dose may be lowered. If you are taking less than 800 mg of imatinib,
      you can take your dose once per day or divided in two doses. Imatinib mesylate should be
      taken with a large glass of water. Bottles containing the tablets will be given to the
      patient every 6 months. Unused supplies must be returned at the end of the study.

      After completing 3 to 12 months of therapy, response to imatinib mesylate will be evaluated.
      If the response is good, treatment with imatinib mesylate alone will be continued. Treatment
      may be continued for up to 20 years, or as long as it is judged best to control the leukemia.

      Update: June 2010 Blood tests are recommended 2 times per year. Your doctor will discuss with
      you how often you should have blood tests. Bone marrow will be done if your doctor thinks it
      is necessary to check your disease. You must return to MD Anderson at least once every year.
      You may not need a bone marrow test every visit, but you will have blood drawn to measure the
      amount of disease you have. If the leukemia cannot be found for 2 years or longer on the
      blood test called polymerase chain reaction (PCR) which is done to measure the amount of
      disease you have, your doctor may talk to you about stopping treatment with imatinib. If you
      and your doctor decide to stop your therapy, you will have a blood test for PCR done every 3
      to 6 months. You do not need to return to MD Anderson to have this blood test done. You may
      have the blood taken by your local doctor and mailed to M. D. Anderson. If the leukemia is
      found again by the PCR blood test, your doctor may recommend that you restart treatment with
      imatinib. You may decide to stay on treatment with imatinib even if your PCR blood test does
      not show any sign of leukemia for 2 years or longer.

      This is an investigational study. Imatinib mesylate has been approved in CML. A total of 125
      patients will take part in this study. All will be enrolled at MD Anderson.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Sponsor discontinued providing study drug.
  </why_stopped>
  <start_date>June 2001</start_date>
  <completion_date type="Actual">November 2013</completion_date>
  <primary_completion_date type="Actual">November 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Molecular Response of Complete or Partial Hematologic Remission</measure>
    <time_frame>Response to imatinib mesylate evaluated after completing 3 - 12 months of therapy.</time_frame>
    <description>Complete Hematologic Remission (CHR): normalization &gt;4 weeks of bone marrow (&lt;5% blasts), peripheral blood with White Blood Cells (WBC) &lt;10 x 109/L &amp; no peripheral blasts, promyelocytes or myelocytes; disappearance all signs/symptoms disease. Partial Hematologic Response (PHR) = CHR except persistence of immature cells (myelocytes, metamyelocytes), or splenomegaly &lt; 50% of pretreatment, or thrombocytosis &gt;450x109/L but &lt;50% of pretreatment. Hematologic surveys twice per year with bone aspirations at discretion of treating physician.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Participant Complete Hematologic Remission (CHR) Classified</measure>
    <time_frame>Response to imatinib mesylate evaluated after completing 3 - 12 months of therapy.</time_frame>
    <description>Number of participants with Complete Hematologic Remission (CHR): normalization &gt;4 weeks of bone marrow (&lt;5% blasts), peripheral blood with WBC &lt;10 x 109/L &amp; no peripheral blasts, promyelocytes or myelocytes; disappearance all signs/symptoms disease. CHR further classified according to suppression of Philadelphia chromosome (Ph) by cytogenetics or i Fluorescence In Situ Hybridization (FISH): No cytogenetic response - Ph positive 100% of pretreatment value; Minor cytogenetic response - Ph positive 35-90% of pretreatment value; Partial cytogenetic response - Ph positive 1-34% of pretreatment value; Complete cytogenetic response - Ph positive 0%. Hematologic surveys twice per year with bone aspirations at discretion of treating physician.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">117</enrollment>
  <condition>Myelogenous Leukemia, Chronic, Chronic Phase</condition>
  <arm_group>
    <arm_group_label>Gleevec</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Gleevec 400 mg orally twice daily.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gleevec</intervention_name>
    <description>400 mg orally twice daily</description>
    <arm_group_label>Gleevec</arm_group_label>
    <other_name>imatinib mesylate</other_name>
    <other_name>STI-571</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients age 15 years or older with a diagnosis of Ph-positive or Bcr-positive CML in
             early chronic phase CML (diagnosis &lt; 12 months). Except for hydroxyurea, patients must
             have received no or minimal prior therapy, defined as less than 1 month of prior
             interferon (IFN-a) or ara-C.

          2. Eastern Cooperative Oncology Group (ECOG) performance of 0-2

          3. Serum bilirubin less than 2 mg%, serum creatinine less than 2mg%

          4. Women of pregnancy potential must practice contraception. Women and men must continue
             birth control for the duration of the trial and at least 3 months after the last dose
             of study drug.

          5. Patients must sign an informed consent indicating they are aware of the
             investigational nature of this study, in keeping with the policies of the hospital.

          6. The definitions of CML phases are as follows: a) early chronic phase: time from
             diagnosis to therapy &lt; 12 months, late chronic phase: time from diagnosis to therapy &gt;
             12 months; b) blastic phase: presence of 30% blasts or more in the peripheral blood or
             bone marrow; c) accelerated phase CML: presence of any of the following features:
             peripheral or marrow blasts 15% or more, peripheral or marrow basophils 20% or more,
             thrombocytopenia &lt;100 x 10(9)/L unrelated to therapy, documented extramedullary
             blastic disease outside liver or spleen due to past causes

          7. The definitions of CML phases are as follows: clonal evolution defined as the presence
             of additional chromosomal abnormalities other than the Ph chromosome is part of
             accelerated phase CML. Ph chromosome variants or complex Ph chromosome translocations
             are not considered to indicate disease acceleration. We have recently found clonal
             evolution to have a variable prognostic impact and may be suppressed with IFN-a
             therapy. Hence these patients will be eligible if no other accelerated phase signs are
             present, and analyzed separately.

          8. Inclusion of women and minorities: As per NIH policy, women and members of minorities
             will be included in this protocol as they are referred in the CML population. Their
             distribution is similar to the general referral profiles for CML: about 50% of CML
             patients are females and 25% to 30% are members of minorities. There are no exclusions
             of women or minorities based on the study objectives.

        Exclusion Criteria:

          1. New York Heart Association (NYHA) class 3-4 heart disease

          2. Psychiatric disability (psychosis)

          3. Pregnant or lactating females

          4. Patients in late chronic phase, accelerated phase or blastic phase are excluded.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>15 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jorge E Cortes, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UT MD Anderson Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://mdanderson.org</url>
    <description>University of Texas MD Anderson Cancer Center Official Website</description>
  </link>
  <verification_date>September 2018</verification_date>
  <study_first_submitted>June 3, 2002</study_first_submitted>
  <study_first_submitted_qc>June 3, 2002</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 4, 2002</study_first_posted>
  <results_first_submitted>September 19, 2016</results_first_submitted>
  <results_first_submitted_qc>September 11, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">October 9, 2018</results_first_posted>
  <last_update_submitted>September 11, 2018</last_update_submitted>
  <last_update_submitted_qc>September 11, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">October 9, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Philadelphia chromosome positive</keyword>
  <keyword>early chronic phase (diagnosis &lt; 12 months)</keyword>
  <keyword>Chronic Myelogenous Leukemia, Chronic Phase</keyword>
  <keyword>Chronic Myelogenous Leukemia</keyword>
  <keyword>CML</keyword>
  <keyword>Gleevec</keyword>
  <keyword>STI571</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myelogenous, Chronic, BCR-ABL Positive</mesh_term>
    <mesh_term>Leukemia, Myeloid, Chronic-Phase</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Imatinib Mesylate</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Recruitment Period: June 11, 2001 to April 25, 2003. All recruitment done in medical settings at University of Texas (UT) MD Anderson Cancer Center.</recruitment_details>
      <pre_assignment_details>Of the 117 participants enrolled, three were excluded before starting: two (2) withdrew from the study prior to initiation of treatment and one (1) was ineligible.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Gleevec</title>
          <description>Gleevec 400 mg orally twice daily.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="114"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="105"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Gleevec</title>
          <description>Gleevec 400 mg orally twice daily.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="114"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="48" lower_limit="17" upper_limit="84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="43"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="114"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Molecular Response of Complete or Partial Hematologic Remission</title>
        <description>Complete Hematologic Remission (CHR): normalization &gt;4 weeks of bone marrow (&lt;5% blasts), peripheral blood with White Blood Cells (WBC) &lt;10 x 109/L &amp; no peripheral blasts, promyelocytes or myelocytes; disappearance all signs/symptoms disease. Partial Hematologic Response (PHR) = CHR except persistence of immature cells (myelocytes, metamyelocytes), or splenomegaly &lt; 50% of pretreatment, or thrombocytosis &gt;450x109/L but &lt;50% of pretreatment. Hematologic surveys twice per year with bone aspirations at discretion of treating physician.</description>
        <time_frame>Response to imatinib mesylate evaluated after completing 3 - 12 months of therapy.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Gleevec</title>
            <description>Gleevec 400 mg orally twice daily.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Molecular Response of Complete or Partial Hematologic Remission</title>
          <description>Complete Hematologic Remission (CHR): normalization &gt;4 weeks of bone marrow (&lt;5% blasts), peripheral blood with White Blood Cells (WBC) &lt;10 x 109/L &amp; no peripheral blasts, promyelocytes or myelocytes; disappearance all signs/symptoms disease. Partial Hematologic Response (PHR) = CHR except persistence of immature cells (myelocytes, metamyelocytes), or splenomegaly &lt; 50% of pretreatment, or thrombocytosis &gt;450x109/L but &lt;50% of pretreatment. Hematologic surveys twice per year with bone aspirations at discretion of treating physician.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="114"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>CHR</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="110"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PHR</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Participant Complete Hematologic Remission (CHR) Classified</title>
        <description>Number of participants with Complete Hematologic Remission (CHR): normalization &gt;4 weeks of bone marrow (&lt;5% blasts), peripheral blood with WBC &lt;10 x 109/L &amp; no peripheral blasts, promyelocytes or myelocytes; disappearance all signs/symptoms disease. CHR further classified according to suppression of Philadelphia chromosome (Ph) by cytogenetics or i Fluorescence In Situ Hybridization (FISH): No cytogenetic response - Ph positive 100% of pretreatment value; Minor cytogenetic response - Ph positive 35-90% of pretreatment value; Partial cytogenetic response - Ph positive 1-34% of pretreatment value; Complete cytogenetic response - Ph positive 0%. Hematologic surveys twice per year with bone aspirations at discretion of treating physician.</description>
        <time_frame>Response to imatinib mesylate evaluated after completing 3 - 12 months of therapy.</time_frame>
        <population>Analysis was of the 110 participants who achieved a CHR with a cytogenetic response as described in the outcome measure descriptions.</population>
        <group_list>
          <group group_id="O1">
            <title>Gleevec</title>
            <description>Gleevec 400 mg orally twice daily.</description>
          </group>
        </group_list>
        <measure>
          <title>Participant Complete Hematologic Remission (CHR) Classified</title>
          <description>Number of participants with Complete Hematologic Remission (CHR): normalization &gt;4 weeks of bone marrow (&lt;5% blasts), peripheral blood with WBC &lt;10 x 109/L &amp; no peripheral blasts, promyelocytes or myelocytes; disappearance all signs/symptoms disease. CHR further classified according to suppression of Philadelphia chromosome (Ph) by cytogenetics or i Fluorescence In Situ Hybridization (FISH): No cytogenetic response - Ph positive 100% of pretreatment value; Minor cytogenetic response - Ph positive 35-90% of pretreatment value; Partial cytogenetic response - Ph positive 1-34% of pretreatment value; Complete cytogenetic response - Ph positive 0%. Hematologic surveys twice per year with bone aspirations at discretion of treating physician.</description>
          <population>Analysis was of the 110 participants who achieved a CHR with a cytogenetic response as described in the outcome measure descriptions.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="110"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>No cytogenetic response</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Minor cytogenetic response</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Partial cytogenetic response</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Complete cytogenetic response</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="105"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Total duration of therapy anticipated to be 15-20 years. Adverse events were collected from initiation of treatment, every 6 months yearly. Overall study period was June 2001 to August 2013.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Gleevec</title>
          <description>Gleevec 400 mg orally twice daily.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="45" subjects_at_risk="114"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Bleeding</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Hemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="114"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Arthritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Cardiac Arrythmia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Cardiac; NOS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Cardiovascular Accident</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Chest Pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Left Ventricular Systolic Dysfunction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Pericarditis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Congestive Heart Failure</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Left Ventricular Diastolic Dysfunction</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Atrial Fibrallation</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Angioplasty</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Coronary artery bypass grafting (CABG) required</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="114"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Eye Irritation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="114"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhea/Vomiting</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Prolapse Colon</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Small Bowel Obstruction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Gallbladder disorder - Cholecystectomy</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="114"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Secondary Malignancy</sub_title>
                <counts group_id="E1" events="8" subjects_affected="7" subjects_at_risk="114"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Increased Liver Enzymes</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="114"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" events="10" subjects_affected="9" subjects_at_risk="114"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="114"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="114"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Hip Replacement Surgery</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="114"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="114"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Hematuria</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="114"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Ruptured Ovarian Cyst</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Pregnancy</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="114"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pulmonary Edema</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Pulmonary Insufficiency</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Shortness of Breath</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Pleural Effusion</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="114"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Rotator cuff Repair</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Surgery</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Surgery Abdominal Mass</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Elective Surgery</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="114"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="59" subjects_at_risk="114"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Chest Pain</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="114"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="114"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Secondary Malignancy</sub_title>
                <counts group_id="E1" events="8" subjects_affected="7" subjects_at_risk="114"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" events="10" subjects_affected="9" subjects_at_risk="114"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Elective Surgery</sub_title>
                <counts group_id="E1" events="7" subjects_affected="6" subjects_at_risk="114"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Jorge Cortes, MD/Professor, Leukemia Department</name_or_title>
      <organization>University of Texas (UT) MD Anderson Cancer Center</organization>
      <phone>713-794-5783</phone>
      <email>CR_Study_Registration@mdanderson.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

